Targeting Oestrogen Receptor Signalling in Breast Cancer Therapy
Gespeichert in:
| Titel: | Targeting Oestrogen Receptor Signalling in Breast Cancer Therapy |
|---|---|
| Autoren: | Howell, Sacha J, Howell, Anthony |
| Quelle: | Advances in Experimental Medicine and Biology ISBN: 9783031708749 Howell, S J & Howell, A 2025, Targeting Oestrogen Receptor Signalling in Breast Cancer Therapy. in A Guide to Breast Cancer Research : From Cellular Heterogeneity and Molecular Mechanisms to Therapy. Advances in Experimental Medicine and Biology, vol. 1464, Springer Nature, pp. 449-474. https://doi.org/10.1007/978-3-031-70875-6_22 |
| Verlagsinformationen: | Springer Nature Switzerland, 2025. |
| Publikationsjahr: | 2025 |
| Schlagwörter: | Selective Estrogen Receptor Modulators, Antineoplastic Agents, Hormonal/therapeutic use, Antineoplastic Agents, Hormonal, Aromatase Inhibitors, Antineoplastic Agents, Breast Neoplasms, Breast Neoplasms/drug therapy, Estrogen Receptor Antagonists/therapeutic use, Receptors, Estrogen, Signal Transduction/drug effects, Selective Estrogen Receptor Modulators/therapeutic use, Receptors, Humans, Animals, Female, Estrogen/metabolism, Receptors, Estrogen/metabolism, Hormonal/therapeutic use, Molecular Targeted Therapy/methods, Aromatase Inhibitors/therapeutic use, Signal Transduction |
| Beschreibung: | There has been over 130 years of research into the treatment of breast cancer using approaches that target oestrogen receptor signalling. Here, we summarise the development of the key pillars of such endocrine therapy, namely, oestrogen deprivation, achieved through ovarian suppression and/or aromatase inhibition, and oestrogen receptor blockade, through selective oestrogen receptor modulators, downregulators and novel compounds entering early phase development. The translation of these compounds from advanced to early breast cancer settings is discussed with a focus on the placebo-controlled breast cancer prevention studies to most accurately describe the side effect profiles of the main approaches. |
| Publikationsart: | Part of book or chapter of book Article |
| Sprache: | English |
| DOI: | 10.1007/978-3-031-70875-6_22 |
| Zugangs-URL: | https://pubmed.ncbi.nlm.nih.gov/39821038 https://research.manchester.ac.uk/en/publications/79ac5dd8-2fdd-4734-bc60-6c0a12c34d02 https://doi.org/10.1007/978-3-031-70875-6_22 |
| Rights: | Springer Nature TDM |
| Dokumentencode: | edsair.doi.dedup.....16b52b9e5b613b37b4839e56ddacd4d5 |
| Datenbank: | OpenAIRE |
Nájsť tento článok vo Web of Science | Abstract: | There has been over 130 years of research into the treatment of breast cancer using approaches that target oestrogen receptor signalling. Here, we summarise the development of the key pillars of such endocrine therapy, namely, oestrogen deprivation, achieved through ovarian suppression and/or aromatase inhibition, and oestrogen receptor blockade, through selective oestrogen receptor modulators, downregulators and novel compounds entering early phase development. The translation of these compounds from advanced to early breast cancer settings is discussed with a focus on the placebo-controlled breast cancer prevention studies to most accurately describe the side effect profiles of the main approaches. |
|---|---|
| DOI: | 10.1007/978-3-031-70875-6_22 |